AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 3 - (NewsRx.com & NewsRx.net) -- CD8+ T cells from cervical cancer patients specific to type 16 E7 peptide also react with coronavirus NS2 protein.
According to a study from Germany, "Human papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are required for cellular transformation and represent candidate targets for HPV-specific and MHC-I restricted CD8+ T-cell responses in patients with cervical cancer.
"Recent evidence suggests that cross-reactivity represents the inherent nature of the T-cell repertoire. We identified HLA-A2 binding HPV16 E7 variant peptides from human, bacterial, or viral origin which are able to drive CD8+ T-cell responses directed against wild-type HPV16 E7 amino acids 11 to 19/20 (E7(11-19/20)) epitope YMLDLQPET(T) in vitro," wrote K. Nilges and coauthors.
"CD8+ T cells reacting to the HLA-A2 presented peptide from HPV16 E7(11-19(20)) recognized also the HLA-A2 binding peptide TMLDIQPED (amino acids 52-60) from the human coronavirus OC43 NS2 gene product. Establishment of coronavirus NS2-specific, HLA-A2 restricted CD8+ T-cell clones and ex vivo analysis of HPV16 E7 specific T cells obtained by HLA-A2 tetrAm guided sorting from PBL, or tumor infiltrating lymphocytes obtained from patients with cervical cancer, showed that crossreactivity with HPV16 E7(11-19(20)) and coronavirus NS2(52-60) represents a common feature of this antiviral immune response defined by cytokine production.
"Zero of 10 patients with carcinoma in situ neoplasia and 3 ...